On a new deal spree, Re­gen­eron buys in­to ISA in pur­suit of a check­point com­bo

Re­gen­eron and Sanofi $SNY aim to field the sixth new en­try in the PD-1/L1 space next year, and like their ri­vals they have some big plans for fol­lowup ap­provals in a rush to com­mand new mar­ket nich­es.

This morn­ing Re­gen­eron $REGN an­nounced that it will pur­sue a com­bi­na­tion pro­gram match­ing its check­point cemi­plimab with an HPV16-tar­get­ing drug from the Dutch biotech ISA for cer­vi­cal and head-and-neck can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER